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Chronic kidney disease coexists with metabolic syndrome
and this relationship may be apparent before overt
manifestations of cardiovascular disease. To investigate early
stages of the natural history of associations between renal
function and metabolic syndrome, we phenotyped 1572
young (mean age¼ 18.4 years), apparently healthy men for
metabolic risk factors and estimated their creatinine
clearance based on the Cockcroft–Gault equation. High
metabolic risk (clustering of at least three metabolic risk
factors) was revealed in 8.7% (137) of the subjects and was
associated with a 6.9-fold increase in the odds of glomerular
hyperfiltration (95% confidence interval (CI): 3.9–11.5) when
compared to reference (from none to two metabolic risk
factors). Overweight, elevated blood pressure, and low
high-density lipoprotein (HDL) cholesterol increased the
multivariate-adjusted odds ratio of glomerular hyperfiltration
to 6.6 (95% CI: 3.8–11.6), 1.8 (95% CI: 1.0–3.0), and 2.5 (95% CI:
1.5–4.3), respectively. Systolic and diastolic blood pressures
clustered together with leptin in the factor analysis and this
blood pressure–adiposity component correlated with
estimated creatinine clearance (r¼ 0.329, Po0.0001) and
explained on its own 10.2% of the variance in the estimated
renal function. Our data reveal the silent epidemics of
metabolic risk among young, apparently healthy men.
Furthermore, the results indicate that high metabolic risk is
associated with glomerular hyperfiltration before overt
manifestations of cardiovascular disease.
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Decreased circulating concentrations of high-density lipo-
protein (HDL) cholesterol (HDL), increased plasma levels of
triglycerides (TG) and glucose, elevated blood pressure and
obesity are well-known metabolic risk determinants.1 Clus-
tering of at least three of these factors fulfills the criteria of
metabolic syndrome (MS) according to the Third Report of
the National Cholesterol Education Program.1 MS precedes
several common morbidities including cardiovascular dis-
ease2 and type 2 diabetes3, and the recent studies suggest that
it may contribute to chronic kidney disease (CKD).4
Accumulating data indicate that in subjects recruited from
the general population, MS is associated with increased risk
of decline in glomerular filtration,5 whereas in patients
with CKD, major metabolic risk factors (such as elevated
TG and low HDL-cholesterol) accelerate progression to
end-stage renal disease.6 Furthermore, elevated metabolic risk
augments the risk of microalbuminuria5 and proteinuria.7
Collectively, these data from middle-aged popula-
tions provide compelling evidence that increased metabolic
risk may exert a negative effect on renal function and
structure.
The increasing prevalence of overweight and type 2
diabetes in young adults and children indicates that
metabolic risk continuum begins in young adulthood or
indeed in childhood.8 Consequently, the natural history of
the associations between MS and its comorbidities, including
CKD, may also begin early in life. Using a well-phenotyped,
epidemiologically representative sample of apparently healthy
young men, we investigated whether increased metabolic risk
could be associated with markers of renal function before
overt clinical manifestations of cardiovascular disease.
RESULTS
High prevalence of MS risk factors among apparently young
healthy men
General characteristics of the study group are presented in
Table 1. Out of five major metabolic risk factors, the most
common was decreased HDL-cholesterol, 38.1% (599),
followed by elevated blood pressure, 24.1% (380); over-
weight, 18.4% (290); increased circulating concentrations of
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TG, 12.9% (203); and elevated plasma glucose levels, 8.4%
(133).
No metabolic risk factors were seen in 35.0% (551) men.
One metabolic risk factor was confirmed in 39.4% (619) of
subjects. Two, three, four, and five metabolic risk factors
clustered together in 16.9% (265), 6.2% (98), 2.2% (35), and
0.3% (4) of subjects, respectively. High metabolic risk
(defined as clustering of at least three metabolic risk factors)
was revealed in 8.7% (137) of the participants.
Estimated creatinine clearance increases with escalating
metabolic risk
There was a gradual increase in absolute estimated creatinine
clearance (Ccr) across the cumulating number of metabolic
risk factors (Figure 1). Indeed, the 75% percentile of crude
Ccr in healthy men (no metabolic risk factors) corresponded
to the median and 25% percentile of Ccr in subjects with 3
and 4 or more metabolic risk factors, respectively. Adjust-
ment for obvious cofounders, age and fat-free mass (FFM),
did not attenuate this difference (Po0.0001). Inclusion of
insulin-resistance index (measured by homeostatic model
assessment insulin-resistance index (HOMA-IR)) in the
adjustment analysis did not abolish the difference in Ccr
among the men representing the whole spectrum of
metabolic risk (Po0.0001).
Hyperfiltration is associated with elevated metabolic risk but
not with hyperglycemia
Glomerular hyperfiltration was exhibited by 4.1% (65) of
men according to the previously published criteria.9 High
metabolic risk was associated with a 6.9-fold increase in the
odds of hyperfiltration (CI: 3.9–11.5, Po0.0001) when
compared with the low metabolic risk group (subjects with
less than 3 metabolic risk factors). Quantitative indicators of
metabolic profile were worse in hyperfiltrators when
compared with normofiltrators (Table 2). Paradoxically,
hyperfiltration was not associated with hyperglycemia; in
fact, median plasma glucose levels were lower in men with
hyperfiltration compared with normofiltrators (Table 2).
Crude and adjusted odds ratios of glomerular hyperfiltra-
tion in relation to individual metabolic risk factors are
presented in Table 3. Elevated blood pressure, low HDL, high
circulating concentrations of TG (according to the Third
Report of the National Cholesterol Education Program
criteria1), and being overweight were associated with the
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Figure 1 | Absolute creatinine clearence according to the number
of metabolic risk factors. Values are medians with 25–75%
interquartile ranges. P, statistical significance in the Kruskal–Wallis test
after adjustment for age, fat-free mass, and insulin-resistance index
(based on HOMA-IR). Numbers of subjects in each of the subgroups: 0
risk factors, 631; 1 risk factor, 638; 2 risk factors, 223, 3 risk factors, 62,
and 4 or 5 risk factors, 18.
Table 1 | Demographic and clinical characteristics of the
subjects
Phenotype Values
N 1572
Age (years) 18.471.3
Weight (kg) 70.8 (65.0–78.0)
Height (m) 1.78 (1.74–1.83)
BMI (kg/m2) 22.3 (20.6–24.2)
FFM (kg) 56.6 (53.1– 60.2)
SBP (mm Hg) 118.3 (110.0–126.7)
DBP (mm Hg) 73.3 (69.6–80.0)
TC (mmol/l) 4.0 (3.4–4.6)
LDL (mmol/l) 2.4 (1.8–2.9)
HDL (mmol/l) 1.1 (0.9–1.3)
TG (mmol/l) 0.9 (0.7–1.3)
Glucose (mmol/l) 4.7 (4.2–5.1)
Insulin (mU/ml) 7.3 (5.8–10.1)
HOMA-IR 1.5 (1.2–2.1)
Creatinine (mmol/l) 79.4 (72.3–87.0)
Creatinine clearance (ml/min) 137.7 (122.3–155.7)
Smokers 30.0% (526)
Alcohol drinkers 68.0% (1069)
BMI, body mass index; DBP, diastolic blood pressure; FFM, fat-free mass; HDL, high-
density cholesterol; HOMA-IR, homeostatic model assessment insulin-resistance
index; LDL, low-density cholesterol; SBP, systolic blood pressure; TC, total
cholesterol; TG, triglycerides.
Continuous variables are presented as means7s.d. or medians with 25–75%
interquartile ranges. Categorical variables are presented as percentages and
absolute values in parentheses.
Table 2 | Indicators of cardiovascular and metabolic risk in
hyperfiltrators and normofiltrators
Phenotype Hyperfiltrators Normofiltrators P-value
N 65 1507
Age (years) 18.271.0 18.471.3 0.13
Ccr (ml/min) 207.5 (198.4–222.3) 136.4 (121.6–153.4) o0.0001
Creatinine (mmol/l) 66.3 (59.7–70.7) 79.8 (73.1–87.3) o0.0001
BMI (kg/m2) 26.9 (24.2–30.2) 22.2 (20.5–24.1) o0.0001
FFM (kg) 64.7 (60.7–68.6) 56.4 (53.1–59.7) o0.0001
SBP (mm Hg) 128.3 (120–139.3) 118.3 (110.0–125.6) o0.0001
DBP (mm Hg) 76.7 (69.8–83.3) 72.5 (69.6–80.0) 0.0074
TC (mmol/l) 3.8 (3.0–4.6) 4.0 (3.4–4.6) 0.2656
LDL (mmol/l) 2.2 (1.7–2.9) 2.4 (1.8–2.9) 0.3569
HDL (mmol/l) 0.9 (0.8–1.1) 1.1 (0.9–1.3) o0.0001
TG (mmol/l) 1.2 (0.8–1.9) 0.9 (0.7–1.3) 0.0007
Glucose (mmol/l) 4.5 (4.0–4.9) 4.7 (4.2–5.1) 0.0215
Log insulin (mU/ml) 0.95 (0.84–1.1/) 0.86 (0.77–1.0) 0.0006
HOMA-IR 1.7 (1.3–2.4) 1.5 (1.2–2.1) 0.0284
BMI, body mass index; Ccr, creatinine clearance; DBP, diastolic blood pressure; FFM,
fat-free mass; HDL, high-density cholesterol; HOMA-IR, homeostatic model assess-
ment insulin-resistance index; LDL, low-density cholesterol; SBP, systolic blood
pressure; TC, total cholesterol; TG, triglycerides.
Continuous variables are presented as means7s.d. or medians with 25–75%
interquartile ranges.
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increased odds ratios of glomerular hyperfiltration in the
crude analysis (Table 3). After adjustment for other
demographic and metabolic variables, only high body mass
index (BMI), elevated blood pressure and low HDL remained
associated with the increased odds ratio of hyperfiltration
(Table 3).
Crude and adjusted associations between leptin and
estimated Ccr
Leptin was associated with estimated Ccr (r¼ 0.538,
Po0.001 and T¼ 7.93, Po0.0001 in Pearson’s correlation
and regression analysis, respectively), and this association
remained significant after controlling for BMI in the multiple
regression analysis (T¼ 2.54, P¼ 0.012). Inclusion of leptin
and major elements of metabolic risk in the multivariate
factor analysis has resulted in extraction of four major
independent components that explained 70.9% of variance in
the metabolic risk variables within this stratum of data
(Table 4). The insulin sensitivity factor (driven by HOMA-IR
and log insulin), blood pressure–adiposity factor (driven by
systolic and diastolic blood pressures as well as leptin), lipid
factor (driven by HDL-cholesterol and TG), and mixed
metabolic factor (driven by glucose and low-density lipo-
protein cholesterol) accounted for 21.6, 20.5, 15.8, 13.0% of
the variance within the stratum of metabolic risk data,
respectively (Table 4). Of these, only the blood pressure–
adiposity factor was significantly, linearly correlated with
estimated Ccr (r¼ 0.329, Po0.0001) and explained on its
own 10.2% of the variance in Ccr in the multiple regression
analysis (T¼ 4.32, Po0.0001).
DISCUSSION
One of the major findings from this study is the evidence for
strikingly high prevalence of major metabolic risk factors
among apparently healthy, young men recruited from the
general population. Indeed, only less than half of the subjects
had no metabolic risk factors. Moreover, at least three
metabolic risk factors clustered together almost in one in 10
of the subjects. These data reveal an early beginning of the
natural history of MS, way before the manifestations of
cardiovascular or renal disease. Furthermore, our results
support the notion that overt cardiovascular disease has its
roots early in youth. Most importantly, in light of general low
awareness of cardiovascular disease risk among young
subjects,10 these alarming data stress the importance of
recognizing the silent epidemic of MS among apparently
healthy, generally lean men.
We also showed that elevated metabolic risk was
associated with renal function. Specifically, the increasing
metabolic risk was associated with a progressive elevation in
estimated Ccr and conversely glomerular hyperfiltration was
related to high cardiovascular risk profile. Both anthropo-
metric and biochemical indices of adiposity and, to a smaller
extent, elevated blood pressure were implicated as major
determinants of glomerular hyperfiltration. These results are
in agreement with well-documented contributions of hemo-
Table 3 | Crude and adjusted odds ratios of glomerular hyperfiltration in relation to metabolic risk factors
Variable
Crude Multivariate-adjusted model 1 Multivariate-adjusted model 2
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
mBP 2.8 (1.7–4.7) o0.0001 1.9 (1.1–3.2) 0.026 1.8 (1.0–3.0) 0.047
mGlucose 1.3 (0.6–3.0) 0.483 0.9 (0.4–2.2) 0.887 0.8 (0.3–2.1) 0.703
kHDL 3.1 (1.8–5.2) o0.0001 2.5 (1.5–4.4) 0.001 2.5 (1.5–4.3) 0.001
mTG 3.2 (1.9–5.6) o0.0001 1.6 (0.9–2.9) 0.138 1.6 (0.9–3.1) 0.124
mBMI 8.6 (5.1–14.5) o0.0001 6.4 (3.7–11.2) o0.0001 6.6 (3.8–11.6) o0.0001
mBMI, body mass index X25 kg/m2; mBP, blood pressure X130/85 mm Hg or antihypertensive treatment; mGlucose, serum glucose X6.1 mmol/l; kHDL, HDL-cholesterol
levels o1.04 mmol/l; mTG, triglyceride levels X1.7 mmol/l.
Model 1: BP, glucose, HDL, TG, and BMI included as covariates.
Model 2: BP, glucose, HDL, TG, BMI, age, alcohol consumption, smoking, and log insulin serum concentrations included as covariates.
Table 4 | Factor analysis of the metabolic variables: factor loadings after orthogonal varimax rotation
Variable Insulin sensitivity factor Blood pressure-adiposity factor Lipid factor Mixed metabolic factor Communality
Age 0.347 0.174 0.368 0.080 0.293
SBP 0.125 0.865 0.078 0.030 0.771
DBP 0.029 0.886 0.040 0.120 0.803
Glucose 0.210 0.118 0.191 0.861 0.836
HOMA-IR 0.942 0.121 0.033 0.109 0.914
Log insulin 0.946 0.148 0.011 0.006 0.918
TG 0.300 0.218 0.692 0.016 0.616
HDL 0.198 0.055 0.828 0.006 0.728
LDL 0.228 0.221 0.399 0.708 0.761
Leptin 0.125 0.581 0.272 0.158 0.452
%Variance 21.6 20.5 15.8 13.0 70.9
DBP, diastolic blood pressure; HDL, high-density cholesterol; HOMA-IR, homeostatic model assessment insulin resistance index; LDL, low-density cholesterol; SBP, systolic
blood pressure; TG, triglycerides. Bold values represent variables with loadings over 0.4 in factor analysis.
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dynamic and metabolic factors to renal hyperperfusion.11–12
One of the major drivers of this association is likely adipose
tissue, a source of bio-molecules with well-documented
effects on glomerular structure and function.13–15 Indeed,
several adipocytokines including resistin and adiponectin
were associated with glomerular filtration rate (GFR) in
patients with CKD and type 1 diabetes.14–15 Moreover,
hyperleptinaemia was linked to glomerular hyperfiltration in
experimental model of type 2 diabetes,16 and the role of
leptin as a potent stimulator of proliferation within major
cellular compartments of the glomeruli was also well-
documented.13 Finally, adipocytokines genes including the
leptin receptor were overexpressed in the glomeruli of
patients with biopsy-proven obesity-related glomerulopathy
when compared to the normal controls.17 Collectively, these
data suggest that adipocytokines may mediate, at least in
part, the observed association between increased total
adiposity and glomerular hyperfiltration with a potential to
foster the development of glomerular dysfunction and
damage.
Association between hypertension and the increased odds
of glomerular hyperfiltration, however modest, is not
surprising as elevated blood pressure is recognized as a
driver of increase in glomerular capillary hydraulic pressure
and glomerular filtration.11,18 Clustering of leptin levels with
blood pressure in the factor analysis reflects a common co-
existence of overweight and hypertension and suggests that
adipose tissue and elevated BP may indeed interact additively
in promotion of the pro-hyperfiltrative phenotype in men
with high metabolic risk. This concept is indeed supported by
previously documented combined effect of overweight and
hypertension on increased filtration fraction, and albumin
excretion rate in a predominantly male population.19
However, the mechanistic explanation of this association
remains to be elucidated. In addition, future studies
are warranted to dissect individual contribution of
both systolic and diastolic blood pressure to the pro-
hyperfiltrative phenotype. Low number of subjects with
exclusively elevated systolic blood pressure and diastolic
blood pressure among hyperfiltrators (nine and one men,
respectively) did not permit us to address this issue in the
current analysis.
Interestingly, elevated plasma glucose levels were not
associated with any change in the odds of glomerular
hyperfiltration. In fact, circulating concentrations of glucose
were lower in hyperfiltrators when compared with normo-
filtrators. Thus, it is unlikely that hyperglycemia could be a
major driver of glomerular hyperfiltration in young men with
high metabolic risk. Although hyperfiltrators in our study
exhibited lower insulin sensitivity compared with the control
group, adjustment for markers of insulin resistance did not
account fully for the difference in Ccr among subjects with
different levels of metabolic risk, and insulin sensitivity factor
was not associated with Ccr in the factor analysis. These data
clearly show that the observed increase in estimated Ccr
among men with high metabolic risk is regulated by the
mechanisms other than those observed in the early stage of
diabetic kidney disease.20
The findings of our study provide a unique insight into
the natural history of CKD in patients with MS. Major
metabolic risk factors increase the risk of CKD4 and the MS
itself is associated with high odds ratio of CKD among
middle-aged and elderly subjects.5 As hyperfiltration is a
predictor of microalbuminuria21 and occurs in patients with
obesity-related nephropathy12 before the end-stage renal
disease, increased Ccr in young subjects with elevated
metabolic risk may be interpreted as an early, and possibly
reversible, marker of target organ damage. However, whether
metabolic-related glomerular hyperfiltration early in life is
associated with higher risk of CKD in the future remains to
be confirmed in prospective studies.
Our study has a number of limitations. It should be
acknowledged that weight was present in formulas used to
estimate both Ccr and BMI. Consequently, association
between the estimated renal function and overweight might
be, at least to some extent, explained by the mathematical
similarities in the equations. However, the associations
between Ccr and total adiposity were replicated in a
subsample of subjects in whom leptin concentrations, instead
of BMI, were used as a marker of fat mass. Moreover,
previous studies based on direct assessment of GFR and
indices of adiposity documented that the risk of hyperfiltra-
tion was higher in obese subjects compared with the normal
controls and weight reduction resulted in a significant
decrease in GFR.22 Therefore, irrespective of the presence of
the same parameter in both BMI and Cockcroft–Gault
formulas, our findings are biologically meaningful and are
supported by previous clinical observations.12,22 Finally, it
should be stressed that Cockcroft–Gault equation was shown
previously as a preferred method of estimating filtration in
young subjects with normal or supranormal renal function.23
In contrast, the Modification of Diet in Renal Disease
(MDRD) equation was not validated in men aged 18 years or
younger and was shown to underestimate GFR in healthy
subjects.24 In fact, compared with the Cockcroft–Gault
equation, MDRD formula was associated with a higher
underestimation of the measured 125I-iothalamate GFR in
healthy kidney donors.25 In addition, although weight is not
included in the MDRD equation, the latter correlates
indirectly with body weight measures, including BMI.26
Therefore, in the absence of direct measurement of renal
function and well-validated formula of estimating GFR in
apparently young healthy men with normal and supranormal
renal function, the Cockcroft–Gault equation may be the
least-biased estimator of renal function in the current
analysis. Future studies are warranted to validate different
methods of estimated GFR against the directly measured GFR
in large cohorts of apparently young healthy subjects with
normal renal function and hyperfiltration.
We should also stress that as the recruitment of
participants in our study began before the publication of
the most widely used criteria of MS;1 the subjects were not
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phenotyped for waist circumference, a well-accepted marker
of abdominal obesity at present.1 However, estimates of
associations between waist circumference and BMI in
adolescents showed their excellent correlations.27 In addition,
previous observations confirmed utility of BMI as a
substitute of waist circumference in prediction of MS in
men from the West of Scotland Coronary Prevention Study
(WOSCOPS).3
Finally, the limits of the cross-sectional character of this
study do not allow us to attribute causation to the detected
associations. Future prospective studies are certainly needed
to confirm our findings. Nevertheless, epidemiologically
representative sample of subjects, thorough clinical pheno-
typing, no bias introduced by comorbidities or medication
confirm the robust character of our data.
In summary, our study has provided strong evidence for a
‘silent epidemic’ of metabolic risk factors among apparently
young healthy men. We also found that high metabolic risk,
in particular elevated blood pressure as well as indices of total
adiposity, are associated with glomerular hyperfiltration
before overt clinical manifestation of cardiovascular disease.
Future studies will focus on confirmation of these findings in
long-term prospective observations, dissection of the rela-
tionship between adipose tissue and glomerular hemody-
namics as well as determination of the precise
pathophysiological mechanisms behind these associations.
MATERIALS AND METHODS
A sample of 1754 apparently young, healthy, white subjects included
in this project consisted of 1157 men from the previously described
Young Men Cardiovascular Association (YMCA) Study cohort28 and
additional 597 young, healthy males recruited later based on the
same study protocol from eight additional randomly selected
secondary schools in the same southern region of Poland (YMCA
extension). The following were criteria of inclusion: age – at least 16
years, self-declared good health, and willingness to provide blood
sample for further biochemical and genetic analysis. Out of 1754
men, 182 subjects were excluded from the current analysis either
because of incomplete clinical biochemical information or chronic
renal disease diagnosed based on the creatinine levels and Ccr. This
left 1572 subjects eligible for the current analysis.
Apart from antihypertensive medication (reported by 20 men),
no other therapeutics were taken by the participants at the
time of recruitment. The study was approved by a local Bioe-
thical Committee and the subjects gave informed consent for
participation.
Clinical phenotyping protocol was described in detail in our
previous study.28 In brief, clinical history was taken by standardized,
coded questionnaires. Blood pressures were measured in triplicate
using a mercury sphygmomanometer according to the standard
protocol.28 Height and weight measurements were taken under
standard conditions and used in calculation of BMI, a well-accepted
measure of total adiposity.29 Fat-free mass (FFM) was estimated
based on anthropometric data using previously validated equation:
FFM¼ 5.1 height1.14weight0.41.30
Lipid profile was measured as described elsewhere.28 Plasma
glucose levels were estimated using a hexokinase enzymatic method.
Circulating creatinine levels were assessed based on the kinetic Jaffe
reaction on a Cobas Bio-Autoanalyzer. Insulin was measured using a
radioimmunoassay (DSL) on 1470 Wizard automatic gamma
counter. HOMA-IR ((plasma insulin plasma glucose)/22.5) was
used an indicator of insulin resistance. Circulating concentrations of
leptin (a biochemical marker of adipose tissue) were measured
according to the protocol described previously31 on 160 samples of
eligible subjects randomly selected from the YMCA population.
All biochemical analyses were performed on fasting samples.
Four major metabolic risk factors (HDL, blood pressure, TG, and
glucose) were categorized based on the previously recommended
cut-off values from the Third Report of the National Cholesterol
Education Program guidelines.1 Overweight was diagnosed in
subjects with BMIX25 kg/m2.32 We used this lower BMI cut-off in
this cohort of generally young, lean men since the higher cut-off of
30 kg/m2 (obesity) would have only captured a minority of
individuals with high metabolic risk.
The Cockcroft–Gault equation ((140–age)weight)/
(72 creatinine) was used as an estimator of Ccr – a well-accepted
index of predicted renal function.33 Ccr was expressed in absolute
values (ml/min) and not indexed per 1.73 m2 of body surface area,
as indexing of GFR by body surface area was shown to obscure a
genuine association between renal function and total adiposity.34
Glomerular hyperfiltration was defined as Ccr over the meanþ 2
s.d., as suggested elsewhere.9
Statistical analysis
Data are presented as means7s.d. or median and 25–75%
interquartile range. Kolmogorov–Smirnov test was used as a test
for normality. Normally distributed quantitative parameters were
analyzed using the parametric one-way analysis of variance.
Differences in quantitative variables that did not pass the normality
test were assessed by the nonparametric Kruskal–Wallis test.
Adjustment analysis was based on comparisons of residuals obtained
from the multiple regression models.
w2 Test was used to evaluate associations between two
dichotomized qualitative parameters. Pearson’s linear correlation
was employed as a method of computing a coefficient of correlation
(r) between two quantitative variables.
To estimate the crude odds ratio of glomerular hyperfiltration,
each of five classical metabolic risk factors was included as an
independent variable in the binary logistic regression. The adjusted
odds ratios of glomerular hyperfiltration were derived from
multivariate logistic regression models including all five classical
metabolic risk factors simultaneously (model 1) as well as the same
combined set of metabolic risk factors together with age, categorized
alcohol consumption, categorized smoking, and HOMA-IR
(model 2).
Factor analysis, a well-accepted method of studying a range of
variables showing a high level of intercorrelation,35 was used to
identify clusters of phenotypes that contribute to the variance within
the observed metabolic data in a subset of 160 subjects with available
serum leptin levels. Four factors were extracted based on the
principal components method and transformed using an orthogonal
varimax rotation, as described elsewhere.35 In brief, each of these
factors reflects one of four major clusters of phenotypes identified in
the stratum of data from the investigated population. Predominant
metabolic variables within each of four factors were identified by
individual loadings and used in defining the names of the factors.
Accordingly, insulin sensitivity factor, blood pressure–adiposity
factor, lipid factor, and mixed metabolic factor refer to the
components driven by HOMA-IR and log insulin, systolic blood
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pressure, diastolic blood pressure and leptin (blood pressure–adipo-
sity factor), TG, and HDL (lipid factor) as well as glucose and low-
density lipoprotein (mixed metabolic factor). Only variables with
loadings over 0.4 on the extracted metabolic factors were considered
as statistically meaningful. Insulin sensitivity factor, blood pressure –
adiposity factor, lipid factor and mixed metabolic factor were tested
for association with Ccr in Pearson’s linear correlation as well as
multiple regression analysis.
Nominal Po0.05 were considered as statistically significant.
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